ArticleAntibiotics (Basel, Switzerland)2022
Evaluation of Retail Meat as a Source of ESBL
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- ESBL and carbapenemase-producing enteric pathogens in animal-origin foods: a one health perspective.Folia microbiologica · 2026Review
- Emergence of virulent ESBL-producing Escherichia coli in meat with human health implications and control using liposomal cinnamon, oregano, and clove within a One Health framework.Scientific reports · 2026Article
- Molecular characterization of ESBL-producingFrontiers in cellular and infection microbiology · 2026Article
- Intestinal and Extraintestinal Pathotypes ofAntibiotics (Basel, Switzerland) · 2025Article
- Extended-spectrum β-lactamase-producingVeterinary world · 2024Review
- The Global Rise of ESBL-ProducingAnimals : an open access journal from MDPI · 2024Review
- Genomic Analysis of Multidrug-ResistantTropical medicine and infectious disease · 2023Article
- Extended-spectrum β-lactamase-producing E. coli from retail meat and workers: genetic diversity, virulotyping, pathotyping and the antimicrobial effect of silver nanoparticles.BMC microbiology · 2023Article
- Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, the appearance of a group of strains resistant to most β-lactam antibiotics, called extended-spectrum β-lactamases (ESBLs), has greatly impacted the public health sector. The present work aimed to identify the prevalence of ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.